Der Nephrologe

, Volume 7, Issue 1, pp 40–45

Klinisch relevante Faktoren der Progressionshemmung



Neben der Aktivität der renalen Grunderkrankung spielen sekundäre hämodynamische und metabolische Faktoren für die Progression chronischer Nierenerkrankungen eine Rolle. Gesicherte und mögliche Faktoren umfassen Proteinurie, chronische Einnahme nephrotoxischer Medikamente, insbesondere potenziell nephrotoxischer Analgetika, Nikotinabusus, Hyperurikämie, metabolische Azidose sowie möglicherweise auch Phosphatretention und Vitamin-D-Mangel. Therapeutische Ansätze umfassen die Hemmung der Proteinurie mittels medikamentöser Maßnahmen und diätetischer Proteinrestriktion, die Senkung der Harnsäure, den Ausgleich der metabolischen Azidose, die Vermeidung nephrotoxischer Medikamente und die Nikotinkarenz. Kontrollierte Studien zeigen keinen Einfluss einer Lipidsenkung durch Statine oder Ausgleich der renalen Anämie auf die renale Progression.


Progression Proteinurie Hyperurikämie Metabolische Azidose Analgetikanephropathie 

Clinically relevant factors for inhibition of renal progression


Progression of chronic renal disease results from the activity of the underlying renal disease and the presence of secondary hemodynamic and metabolic factors which may further impair renal function. Secondary factors comprise proteinuria, hyperuricemia, metabolic acidosis, long-term intake of nephrotoxic drugs, in particular potentially nephrotoxic analgesics, smoking and possibly phosphate retention and vitamin D deficiency. Therapeutic interventions include reduction of proteinuria by antihypertensive therapy and dietary protein restriction, lowering of uric acid, control of metabolic acidosis, cessation of smoking and avoidance of nephrotoxic drugs. Randomized controlled studies failed to show an influence of lipid lowering by statins and correction of renal anemia on renal progression.


Progression Proteinuria Hyperuricemia Metabolic acidosis Analgesic nephropathy 


  1. 1.
    Baigent L, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377:2181–2192PubMedCrossRefGoogle Scholar
  2. 2.
    Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRefGoogle Scholar
  3. 3.
    Chen YM, Lin SL, Chen SM et al (2008) Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 52:464–474PubMedCrossRefGoogle Scholar
  4. 4.
    Chonchol M, Shlipak MG, Katz R et al (2007) Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 50:239–247PubMedCrossRefGoogle Scholar
  5. 5.
    De Boer IH, Katz R, Chonchol M et al (2011) Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 6:2141–2149CrossRefGoogle Scholar
  6. 6.
    De Brito-Ashurst I, Varaganum M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084CrossRefGoogle Scholar
  7. 7.
    De Zeeuw D, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543–1551CrossRefGoogle Scholar
  8. 8.
    Drüeke TB, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084PubMedCrossRefGoogle Scholar
  9. 9.
    Goicoechea M, Vinuesa SG de, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393PubMedCrossRefGoogle Scholar
  10. 10.
    Hallan SI, Orth SR (2010) Smoking is a risk factor in the progression to kidney failure. Kidney Int 80:516–523CrossRefGoogle Scholar
  11. 11.
    Kao MP, Ang DS, Gandy J et al (2011) Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 22:1382–1389PubMedCrossRefGoogle Scholar
  12. 12.
    Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877–884PubMedCrossRefGoogle Scholar
  13. 13.
    Kovesdy CP, Anderson JE, Kalantar-Zadeh K (2010) Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 73:268–275PubMedGoogle Scholar
  14. 14.
    Levey AS, Greene T, Sarnak MJ et al (2006) Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) study. Am J Kidney Dis 48:879–888PubMedCrossRefGoogle Scholar
  15. 15.
    Li YC (2010) Renoprotective effects of vitamin D analogs. Kidney Int 78:134–139PubMedCrossRefGoogle Scholar
  16. 16.
    Madero M, Sarnak MJ, Wang X et al (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53:796–803PubMedCrossRefGoogle Scholar
  17. 17.
    Mahajan A, Simoni J, Sheather SJ et al (2010) Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78:303–309PubMedCrossRefGoogle Scholar
  18. 18.
    McLaughlin JK, Lipworth L, Chow WH, Blot WJ (1998) Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int 54:679–686PubMedCrossRefGoogle Scholar
  19. 19.
    Navaneethan SD, Pansini F, Perkovic V et al (2009) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2):CD007784Google Scholar
  20. 20.
    Noels LM, Elseviers MM, Broe ME de (1995) Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 10:167–174PubMedGoogle Scholar
  21. 21.
    Obermayr RP, Temml C, Gutjahr G et al (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19:2407–2413PubMedCrossRefGoogle Scholar
  22. 22.
    Orth SR (2004) Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol 15(Suppl 1):58–63CrossRefGoogle Scholar
  23. 23.
    Perneger TV, Whelton PK, Klag MJ (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331:1675–1679PubMedCrossRefGoogle Scholar
  24. 24.
    Pfeffer MA, Burdmann EA, Chen CY et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRefGoogle Scholar
  25. 25.
    Phisitkul S, Khanna A, Simoni J et al (2010) Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77:617–623PubMedCrossRefGoogle Scholar
  26. 26.
    Reichel H, Zeier M, Ritz E (2003) Proteinuria after renal transplantation. Pathogenesis and management. Nephrol Dial Transplant 19:301–305CrossRefGoogle Scholar
  27. 27.
    Robertson L, Waugh N, Robertson A (2007) Protein restriction for diabetic renal disease. Cochrane Database Syst Rev (4):CD002181Google Scholar
  28. 28.
    Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP (2006) Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1:825–831PubMedCrossRefGoogle Scholar
  29. 29.
    Shah SN, Abramowitz M, Hostetter TH, Melamed ML (2009) Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis 54:270–277PubMedCrossRefGoogle Scholar
  30. 30.
    Singh AK, Szczech L, Tang KL et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098PubMedCrossRefGoogle Scholar
  31. 31.
    Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51–59PubMedCrossRefGoogle Scholar
  32. 32.
    Tonelli M, Moyé L, Sacks FM et al (2003) Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138:98–104PubMedGoogle Scholar
  33. 33.
    Weiner DE, Tighiouart H, Elsayed EF et al (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19:1204–1211PubMedCrossRefGoogle Scholar
  34. 34.
    Yamamoto R, Nagasawa Y, Shoji T et al (2010) Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 56:313–324PubMedCrossRefGoogle Scholar
  35. 35.
    Zoccali C, Ruggenenti P, Perna A et al (2011) Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 22:1923–1930PubMedCrossRefGoogle Scholar
  36. 36.
    Zoppini G, Targher G, Chonchol M et al (2011) Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Nephrologisches ZentrumSchwenningenDeutschland

Personalised recommendations